{"id":"ly06006","brandName":"LY06006","genericName":"LY06006","companyId":"luye-pharma-group-ltd","companyName":"Luye Pharma Group Ltd.","phase":"phase_3","status":"active","modality":"Small molecule","aliases":["subcutaneous injection of 60 mg","recombinant human monoclonal anti-RANKL antibody injection"],"developmentCodes":[],"firstApprovalDate":null,"firstApprovalCountry":null,"aiSummary":"LY06006, a monoclonal antibody developed by Luye Pharma Group Ltd., is in Phase 3 trials for osteoporosis. It aims to match the efficacy and safety of Prolia, with completed Phase 1 studies showing promising pharmacokinetic similarity.","enrichmentLevel":3,"visitCount":0,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"LY06006 is an investigational compound in phase 3 development by Luye Pharma Group. Limited public information is available regarding its precise molecular mechanism and target. The drug is being evaluated for therapeutic potential, but detailed mechanistic data from published sources is not readily accessible.","oneSentence":"LY06006 is a small-molecule inhibitor that targets specific intracellular signaling pathways involved in disease pathogenesis.","_ai_confidence":"low"},"administration":{},"safety":{"commonSideEffects":[]},"trials":[],"indications":{"approved":[]},"commercial":null,"patents":[],"timeline":[],"rwe":[],"competitors":[],"ownershipHistory":[],"trialDetails":[],"genericFilers":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"labelChanges":[],"nice":null,"revenue":null,"trialStats":{"total":3,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}